Our goal is to develop a rapid point-of-care test to screen for respiratory virus infections using nasal biomarker testing. This invention is supported by our 5 prior publications and 2 patents. A $300K investment from the Blavatnik fund will enable us to refine our biomarker testing strategy to further  improve accuracy and distinguish respiratory conditions with closely related symptoms (e.g viral infection vs. allergies).